Ultragenyx CMO Bedrosian transitions to advisor; Crombez named new CMO

Ultragenyx Pharmaceutical Inc.

Camille Bedrosian transitions to Strategic Development Advisor effective May 1, 2023.
Eric Crombez promoted to EVP, Chief Medical Officer, effective May 1, 2023.
Bedrosian’s new base salary set at $500,000; target bonus 35%; equity award of 6,900 RSUs and 9,200 options.
Severance benefits under amended Offer Letter based on current $600,000 salary and 50% target bonus if termination before May 2024.
Transition is planned, not a sudden departure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eric Crombez

Executive Vice President, Chief Medical Officer

RARE · Ultragenyx Pharmaceutical Inc.

Effective: 2023-05-01
Filed: March 14, 2023, 7:59 PM ET

Eric Crombez, M.D., the Company’s current Chief Medical Officer for Gene Therapy and Inborn Errors of Metabolism, will assume the role of Executive Vice President, Chief Medical Officer, effective as of the Effective Date.

Role change

Camille L. Bedrosian

Strategic Development Advisor

RARE · Ultragenyx Pharmaceutical Inc.

Effective: 2023-05-01
Successor: Eric Crombez
Filed: March 14, 2023, 7:59 PM ET

On March 14, 2023, Ultragenyx Pharmaceutical Inc. (the “ Company ”) announced that Camille L. Bedrosian, M.D., the Company’s Executive Vice President and Chief Medical Officer, will be transitioning to a new role as Strategic Development Advisor to the Company, effective May 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Crombez was appointed as Executive Vice President, Chief Medical Officer at Ultragenyx Pharmaceutical Inc..

Action: appointed
Role: Executive Vice President, Chief Medical Officer

Exact text from the filing

Eric Crombez, M.D., the Company’s current Chief Medical Officer for Gene Therapy and Inborn Errors of Metabolism, will assume the role of Executive Vice President, Chief Medical Officer, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Camille L. Bedrosian changed role as Strategic Development Advisor at Ultragenyx Pharmaceutical Inc..

Action: transitioning
Role: Strategic Development Advisor

Exact text from the filing

On March 14, 2023, Ultragenyx Pharmaceutical Inc. (the “ Company ”) announced that Camille L. Bedrosian, M.D., the Company’s Executive Vice President and Chief Medical Officer, will be transitioning to a new role as Strategic Development Advisor to the Company, effective May 1, 2023

View on SEC.gov

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.